Cargando…

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study

BACKGROUND: There is concern over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance in people initiating antiretroviral therapy (ART) in low-income and middle-income countries. We assessed the effectiveness and cost-effectiveness of alternative public health...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phillips, Andrew N, Cambiano, Valentina, Nakagawa, Fumiyo, Revill, Paul, Jordan, Michael R, Hallett, Timothy B, Doherty, Meg, De Luca, Andrea, Lundgren, Jens D, Mhangara, Mutsa, Apollo, Tsitsi, Mellors, John, Nichols, Brooke, Parikh, Urvi, Pillay, Deenan, Rinke de Wit, Tobias, Sigaloff, Kim, Havlir, Diane, Kuritzkes, Daniel R, Pozniak, Anton, van de Vijver, David, Vitoria, Marco, Wainberg, Mark A, Raizes, Elliot, Bertagnolio, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843989/ https://www.ncbi.nlm.nih.gov/pubmed/29174084 http://dx.doi.org/10.1016/S2352-3018(17)30190-X

Ejemplares similares

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2018)

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
por: Phillips, Andrew N, et al.
Publicado: (2020)

Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa
por: Phillips, Andrew N., et al.
Publicado: (2017)

Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings
por: Phillips, Andrew, et al.
Publicado: (2014)

Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa
por: Phillips, Andrew N, et al.
Publicado: (2016)

Point-of-Care Viral Load Testing for Sub-Saharan Africa: Informing a Target Product Profile
por: Phillips, Andrew N., et al.
Publicado: (2016)

Moderate Levels of Pretreatment HIV Drug Resistance — Zimbabwe, April–July 2015
por: Da Silva, Juliana, et al.
Publicado: (2017)

Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study
por: Nichols, Brooke E, et al.
Publicado: (2014)

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses
por: Pham, Hanh T., et al.
Publicado: (2016)

Factors Associated with Ever Being HIV-Tested in Zimbabwe: An Extended Analysis of the Zimbabwe Demographic and Health Survey (2010–2011)
por: Takarinda, Kudakwashe Collin, et al.
Publicado: (2016)

How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts’ Opinion and Its Influence on the Projected Public Health Impact
por: Dimitrov, Dobromir T., et al.
Publicado: (2016)

Does nonlocal women’s attendance at antenatal clinics distort HIV prevalence surveillance estimates in pregnant women in Zimbabwe?
por: Wilson, Katherine C., et al.
Publicado: (2017)

Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring
por: von Wyl, Viktor, et al.
Publicado: (2012)

NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved
por: Benedicto, Ana M., et al.
Publicado: (2021)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006
por: Beck, Eduard J., et al.
Publicado: (2011)

Potential Impact and Cost-Effectiveness of Condomless-Sex–Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance
por: Phillips, Andrew N, et al.
Publicado: (2019)

Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-Income Countries
por: Cambiano, Valentina, et al.
Publicado: (2015)

Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy
por: Tossonian, Harout K, et al.
Publicado: (2007)

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa
por: Kityo, Cissy, et al.
Publicado: (2017)

Multiple dosage forms of the NNRTI microbicide dapivirine: product development and evaluation
por: Romano, Joseph
Publicado: (2006)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Cost‐per‐diagnosis as a metric for monitoring cost‐effectiveness of HIV testing programmes in low‐income settings in southern Africa: health economic and modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2019)

Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2022)

High Prevalence of NRTI and NNRTI Drug Resistance Among ART-Experienced, Hospitalized Inpatients
por: Bossard, Claire, et al.
Publicado: (2021)

Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa
por: Phillips, Andrew N., et al.
Publicado: (2016)

Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008–2010
por: Mungati, More, et al.
Publicado: (2016)

Identification of the Critical Sites of NNRTI-Resistance in Reverse Transcriptase of HIV-1 CRF_BC Strains
por: Huang, Yang, et al.
Publicado: (2014)

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
por: Geretti, Anna Maria, et al.
Publicado: (2015)

2507. Transmitted and Acquired NNRTI Resistance in the Philippines: Are Newer Generation NNRTIs a Viable Option?
por: Theresa Dungca, Nina, et al.
Publicado: (2019)

High-resolution view of HIV-1 reverse transcriptase initiation complexes and inhibition by NNRTI drugs
por: Ha, Betty, et al.
Publicado: (2021)

Hepatotoxicity in patients co-infected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin
por: Mankhatitham, W, et al.
Publicado: (2010)

Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile
por: Mori, J, et al.
Publicado: (2010)

Cost-effectiveness of 2NRTI+NNRTI versus 2NRTI+PI as the initial cART regimen
por: Aragão, F, et al.
Publicado: (2010)

Emergency of Primary NNRTI Resistance Mutations without Antiretroviral Selective Pressure in a HAART-Treated Child
por: Machado, Elizabeth S., et al.
Publicado: (2009)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
por: Manosuthi, Weerawat, et al.
Publicado: (2010)

Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects
por: Gupta, Shaili, et al.
Publicado: (2014)

Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care
por: Revill, Paul, et al.
Publicado: (2018)

No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects
por: Vourvahis, M, et al.
Publicado: (2010)

Immunologic and virologic failure after first-line NNRTI-based antiretroviral therapy in Thai HIV-infected children
por: Bunupuradah, Torsak, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_osprgmf3nfegmt6h8dcq2fdch7